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Introduction
As recently as 1980, it was widely held that no therapeutic intervention could reverse the dilated cardio-
myopathic phenotype of  the failing heart once it had developed, thus giving rise to the notion that the devel-
opment of  left ventricular (LV) remodeling and LV dysfunction were irreversible. However, more recent 
clinical studies have shown that medical and device therapies that reduce heart failure (HF) morbidity and 
mortality are accompanied by a reversal of  the pathological LV remodeling (reverse LV remodeling; refs. 1, 
2) that occurs during the development of  HF. Reverse LV remodeling represents the summation of  a series 
of  integrated biological changes in cardiac myocyte size and function, as well as changes in LV structure 
and organization that allow for normalization of  the LV end-diastolic pressure–volume (LVEDP-volume) 
relationship (reviewed in ref. 3). Although many of  the individual components of  reverse LV remodeling 
have been identified and annotated, prior studies have not clarified which of  these cellular processes is 
required for the regression of  pathological LV remodeling. Accordingly, to begin to dissect the biologi-
cal mechanisms that are responsible for reverse LV remodeling, we developed and characterized a condi-
tional transgenic mouse model tetracycline transactivating factor–TRAF2 (tTA-TRAF2) that develops a 
dilated HF phenotype when a proinflammatory transgene, TNF receptor–associated factor 2 (TRAF2), is 
constitutively expressed and that undergoes complete normalization of  LV structure and function when 
the transgene is suppressed. Here, we show that complete normalization of  LV structure and function is 
accompanied by salutary changes in the biology of  the adult cardiac myocyte and that this structural and 
functional recovery is dissociated from changes in the extracellular matrix, as well as from reversal of  gene 
To elucidate the mechanisms for reverse LV remodeling, we generated a conditional (doxycycline 
[dox] off) transgenic mouse tetracycline transactivating factor–TRAF2 (tTA-TRAF2) that develops 
a dilated heart failure (HF) phenotype upon expression of a proinflammatory transgene, TNF 
receptor–associated factor 2 (TRAF2), and complete normalization of LV structure and function 
when the transgene is suppressed. tTA-TRAF2 mice developed a significant increase in LV 
dimension with decreased contractile function, which was completely normalized in the tTA-
TRAF2 mice fed dox for 4 weeks (tTA-TRAF2dox4W). Normalization of LV structure and function 
was accompanied by partial normalization (~60%) of gene expression associated with incident HF. 
Similar findings were observed in patients with dilated cardiomyopathy who underwent reverse 
LV remodeling following mechanical circulatory support. Persistence of the HF gene program was 
associated with an exaggerated hypertrophic response and increased mortality in tTA-TRAF2dox4W 
mice following transaortic constriction (TAC). These effects were no longer observed following TAC 
in tTA-TRAF2dox8W, wherein there was a more complete (88%) reversal of the incident HF genes. 
These results demonstrate that reverse LV remodeling is associated with improvements in cardiac 
myocyte biology; however, the persistence of the abnormal HF gene program may be maladaptive 
following perturbations in hemodynamic loading conditions.
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ontogenies that become dysregulated during LV remodeling. We further show that the failing heart remains 
vulnerable to hemodynamic stress after restoration of  LV structure and function and that this vulnerability 
diminishes over time, after normalization of  the abnormal HF gene program.
Results
Characterization of  tTA-TRAF2 mice. Figure 1 shows that the tTA-TRAF2 mice develop a dilated HF pheno-
type at 12 weeks, characterized by an increased heart weight–to–body weight (HW/BW) ratio (P < 0.05), 
increased LV dilation (P < 0.05), decreased fractional shortening, and adverse LV remodeling as denoted 
by an increased radius-to-thickness (r/h) ratio, consistent with the phenotype observed with constitutive 
overexpression of  TRAF2 using a Myh6 promoter (4). However, the salient finding shown by Figure 1 is 
that HW/BW, LV dilation, and depressed LV fractional shortening, as well as the r/h ratio, were com-
pletely normalized in the tTA-TRAF2dox4W mice that were fed doxycycline (dox) for 4 weeks and were not 
statistically significant from littermate (LM) and LMdox4W control mice (P > 0.05 for all parameters). Light 
microscopic evaluation of  the hearts from tTA-TRAF2 and tTA-TRAF2dox mice at 12 weeks revealed that 
the histological appearance was similar to LM and LMdox4W controls. Notably, there was no discernible 
inflammatory infiltrate by H&E staining (data not shown). Transmission electron microscopic evaluation 
of  the 12-week-old LM and LMdox4W hearts (Figure 1H) revealed a characteristic linear array of  sarcomeres 
and myofibrils. In contrast, the myofibrils in the 12-week-old tTA-TRAF2 mice were less organized — 
with mild loss of  sarcomere registration, disorganized mitochondrial cristae, and accumulation of  protein 
aggregates — consistent with the ultrastructural changes previously reported in transgenic mice with TNF 
expression driven by Myh6 promotion (MHC-TNF mice) and transgenic mice with high copy TRAF2 
expression driven by Myh6 promotion (MHC-TRAF2HC) mice (4, 5).The transmission electron microscopic 
evaluation of  the tTA-TRAF2dox4W hearts revealed a linear arrangement of  sarcomeres and myofibrils, dis-
appearance of  the protein aggregates, and improved organization of  mitochondrial cristae.
Isolated cardiac myocyte and LV contractile function. Cardiac contractility was assessed at the level of  the 
isolated cardiac myocyte and the intact LV chamber in 12-week-old mice by measuring sarcomere shortening 
in freshly isolated cardiac myocytes, as well as LV developed pressure (LVDP), LV +dP/dt and LV –dP/dt 
in isolated buffer–perfused Langendorff  hearts. As shown by the representative sarcomere shortening curves 
in Figure 2A and group data shown in Figure 2B, there was a significant decrease (P < 0.05) in the extent of  
sarcomere shortening in myocytes from the tTA-TRAF2 mice when compared with myocytes from LM mice. 
Remarkably, the extent of  sarcomere shortening in tTA-TRAF2dox4W myocytes was not significantly different 
from myocytes from LMdox4W control mice. Analysis of  intact LV chamber function showed that the contrac-
tile function of  the tTA-TRAF2 hearts was significantly depressed when compared with LM control mice. As 
shown in Figure 2, C and D, LVDP and LV +dP/dt were significantly decreased (P < 0.05 for both), and peak 
-dP/dt was significantly greater (P < 0.05) in the tTA-TRAF2 mice compared with LM controls. Similar to 
our observations in isolated cardiac myocytes, LVDP, + dP/dt, and –dP/dt returned to baseline values in the 
tTA-TRAF2dox4W hearts and were not different statistically (P > 0.05 for each parameter) when compared with 
LMdox4W controls. Analysis of  LV pressure volume curves in Langendorff-perfused hearts showed that the 
LV pressure volume curves of  the tTA-TRAF2dox4W were shifted leftward when compared with tTA-TRAF2 
mouse hearts (Supplemental Figure 1; supplemental material available online with this article; doi:10.1172/
jci.insight.86038DS1). Viewed together, these results suggest that there is a complete normalization of  cardiac 
myocyte shortening, LV chamber contractility, and LV diastolic function in the tTA-TRAF2dox4W mice.
Extracellular matrix. Consistent with our prior observations in transgenic mice with constitutive expres-
sion of  TRAF2, we observed a small but significant (P < 0.05) increase in fibrillar collagen content in the 
tTA-TRAF2 mice when compared with LM controls at 12 weeks of  age (Figure 3). In contrast with the 
findings observed in terms of  LV structure and function, the fibrillar collagen content did not regress in the 
tTA-TRAF2dox4W mouse hearts. As shown in Figure 3B, the fibrillar collagen content in the 12-week-old 
tTA-TRAF2dox4W mice was not significantly different (P > 0.05) from the tTA-TRAF2 and was significantly 
greater (P < 0.05) than 12-week-old LMdox4W mice.
Gene expression profiling. To determine the changes in gene expression that were associated with reverse 
LV remodeling, we performed transcriptional profiling in 12-week-old LM, LMdox4W, tTA-TRAF2, and 
tTA-TRAF2dox4W mouse hearts. Because of  the effects of  dox on gene expression (6), we compared changes 
in gene expression in the tTA-TRAF2 mice vs. LM control mice to characterize genes that were associated 
with LV remodeling, and we compared changes in gene expression in tTA-TRAF2dox4W vs. LMdox4W mice to 
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Figure 1. Characterization of tTA-TRAF2 mice. (A) tTA-TRAF2 mice and LM controls were followed up to 8 weeks of age 
and were then randomized to receive doxycycline in the drinking water or no doxycycline for 4 weeks. (B) Photographs 
of whole hearts and sagittal sections of LM, tTA-TRAF2, LMdox4W, and tTA-TRAF2dox4W mouse hearts at 12 weeks of age. 
(C) Heart weight–to–body weight ratio (HW/BW). (D) Left ventricular end-diastolic diameter (LVEDD).(E) LV fractional 
shortening percent (FS%). (F) LV wall thickness (LVWTh). (G) r/h ratio of LM, tTA-TRAF2, LMdox4W, and tTA-TRAF2dox4W at 
12 weeks of age (n = 6 mice/group). (H) Representative transmission electron micrographs from 12-week LM, tTA-TRAF2, 
LMdox4W, and tTA-TRAF2dox4W mice at ×10,000 and ×20,000 magnification. Protein aggregates are enclosed by the circle. 
Statistical analysis was performed using 2-way ANOVA with Tukey post-hoc analysis. (*P ≤ 0.05 compared with LM 
control.) LM, littermate; LMdox4W, LM mouse fed doxycycline for 4 weeks; r/h ratio, radius/wall thickness.
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characterize changes in genes that were associated with reverse LV remodeling. The salient finding shown 
by Figure 4A is that there were 3,647 genes with significantly altered expression in the LV remodeled 
hearts (P < 0.05), referred to here as incident HF genes, whereas there were 3,383 genes with significantly 
altered expression in the reverse LV remodeled hearts. (P < 0.05). Of  the 3,647 incident HF genes, 58% 
(2,109/3,647) normalized in the tTA-TRAF2dox mice, and hence represent a subset of  reversed incident HF 
genes. In contrast, 42% (1,538/3,647) of  the incident HF genes were also expressed in tTA-TRAF2dox4W 
mice, and thus represent a subset of  incident HF genes that did not normalize during reverse LV remodel-
ing, which we refer to here as persistently dysregulated HF genes. Interestingly, 55% (1,845/3,383) of  the 
genes differentially regulated in the reverse LV remodeled hearts were not detectable during LV remodeling 
(i.e., incident HF genes) and thus represent a set of  genes that are unique to reverse LV remodeling (see 
online Supplemental Table 1 for further characterization).
Unsupervised hierarchical clustering of  expression levels of  changes in gene expression in the LM, 
tTA-TRAF2, LMdox4W, and TRAF2dox4W mice showed that the gene expression profile of  the tTA-TRAF-
2dox4W hearts were distinct from the gene profiles of  the LMdox4W hearts and the tTA-TRAF2 hearts (Figure 
4B). Importantly, the gene expression profile of  the tTA-TRAF2dox4W mice clustered with the tTA-TRAF2 
mice, consistent with incomplete reversal of  the incident HF gene profile in the hearts that underwent 
reverse LV remodeling. Also, unsupervised hierarchical clustering of  the gene profiles for the LM and 
LMdox4W clustered together, suggesting that dox had no dramatic effect on myocardial gene expression at 
Figure 2. Myocyte and LV chamber contractile function of tTA-TRAF2 mice. (A) Representative tracings of sarcomere 
shortening in isolated cardiac myocytes and (B) group data of sarcomere shortening from LM, tTA-TRAF2, LMdox4W, and 
tTA-TRAF2dox4W mouse hearts at 12 weeks of age (5–6/cells/heart from 3 hearts/group). (C) Left ventricular developed 
pressure (LVDP). (D) Peak +dP/dt and (E) peak –dP/dt in 12-week LM (n = 10), tTA-TRAF2 (n = 8), LMdox4W (n = 11), and 
tTA-TRAF2dox4W (n = 5) mouse hearts. Statistical analysis performed using 2-way ANOVA with Tukey post-hoc analysis. 
(*P < 0.05 compared with LM controls.)
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baseline. To further explore the differences in gene profiles in the LV remodeled and reverse LV remodeled 
cardiac phenotypes, we performed a principal component analysis (PCA). As shown in Figure 4C, the 
values for the PCA vectors for the LM and LMdox4W hearts grouped closely together and were aligned differ-
ently from the values for the PCA vectors for the tTA-TRAF2 and tTA-TRAF2dox4W hearts. Consistent with 
the findings with hierarchical clustering, the PCA profiles for the tTA-TRAF2 and the tTA-TRAF2dox4W 
hearts were overlapping.
Kyoto Encyclopedia of  Genes and Genomes (KEGG) functional analysis identified significant changes 
in incident HF gene expression in pathways implicated in both hypertrophic (P = 3.3 × 10–2) and dilated 
cardiomyopathy (DCM) (P = 2.7 × 10–2) in the tTA-TRAF2dox4W reverse LV remodeled hearts (Supplemen-
tal Figure 2). Figure 4D displays a diagram of  the cardiac hypertrophy/DCM–related cardiac myocyte 
genes displayed as either reversed incident HF genes or persistently dysregulated incident HF genes (See 
Supplemental Table 2 for gene lists), whereas Figure 4E illustrates a heat map of  the changes in the reversed 
and persistently dysregulated incident HF genes, grouped functionally into 1 of  5 different cardiac myo-
cyte gene modules, including extracellular matrix, integrin/cytoskeleton, sarcomere, excitation-contraction 
coupling, and metabolism. Evaluation of  the data in Figure 4, D and E, permits several interesting obser-
vations, the first of  which is that normalization of  cardiac myocyte shortening, LV chamber pump perfor-
mance, and LV structure during reverse LV remodeling is not associated with a single gene or a single gene 
module. Rather, reversal of  the LV HF phenotype is accompanied by significant changes in expression 
in multiple genes residing with each of  the gene modules that were examined, save for genes involved in 
metabolism. Second, the changes in reversed incident HF genes were greatest for genes in the extracellular 
matrix/collagen module (18%), followed by the modules for integrin/cytoskeleton (13%), sarcomere (7%), 
excitation-contraction coupling (6%), and metabolism (0%). Conversely, the gene modules that had the 
greatest percentage of  persistently dysregulated incident HF genes were related to metabolism (27%), fol-
lowed by sarcomere (20%), integrin/cytoskeleton (13%), matrix collagen (10%), and excitation contraction 
coupling (5%).
Response to pressure overload. To determine the functional significance of  the abnormal gene expres-
sion profile in the tTA-TRAF2dox4W mice, we subjected 12-week-old tTA-TRAF2dox4W and LMdox4W mice 
to transaortic constriction (TAC). The important finding shown in Figure 5 is that superimposition of  a 
pressure overload resulted in an exaggerated hypertrophic phenotype in the tTA-TRAF2dox4W mice, marked 
by a significant increase in LV mass index (P < 0.03) and LV wall thickness (P < 0.02) 4 weeks following 
TAC. In contrast, there were no significant differences in LV end-diastolic dimension (LVEDD) and the r/h 
ratio in the tTA-TRAF2dox4W and LMdox4W mice 4 weeks after TAC. Importantly, the exaggerated hypertro-
phic response in the pressure overloaded tTA-TRAF2dox4W mice was associated with a significant increase 
in mortality in the tTA-TRAF2dox4W mice when compared with LMdox4W mice (P < 0.04), shown by the 
Kaplan-Meier analysis in Figure 5E.
Figure 3. Myocardial fibrillar 
collagen content in tTA-TRAF2 
mice. (A) Representative 
picrosirius red staining (×400) 
for myocardial fibrillar collagen 
content and (B) group data for 
% collagen volume for LM, tTA-
TRAF2, LMdox4W, and tTA-TRAF-
2dox4W mouse hearts (9–10 fields 
analyzed for n = 3 mice/group). 
Statistical analysis performed 
using 2-way ANOVA with Tukey 
post-hoc analysis. (*P < 0.05 vs. 
LM control.)
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Figure 4. Transcriptional profiling in 12-week LM, tTA-TRAF2, LMdox4W, and 
tTA-TRAF2dox4W mouse hearts. (A) Venn diagram of normalized heart failure 
(HF) genes, persistently dysregulated HF genes, and new reverse remodeled 
genes (see text for details). (B) Unsupervised hierarchical clustering of changes 
in gene expression, and (C) principal component analysis (PCA) of changes in 
gene expression. (D) Illustration of persistently dysregulated and reversed HF 
genes in relation to their anatomic location within the cardiac myocyte. (E) 
Illustration of persistently dysregulated and reversed HF genes in gene mod-
ules relating to cardiac myocyte function (see text for details). The number of 
genes within each module is given in parenthesis (n = 4 hearts per group). Red 
indicates increased gene expression; blue indicates decreased gene expres-
sion relative to LM; Rev, reversed HF genes; PD, persistently dysregulated 
HF genes. Analysis performed with Partek Genomics Suite. LM, littermate; 
LMdox4W, LM mouse fed doxycycline for 4 weeks; r/h ratio, radius/wall thick-
ness, PC, principal component; PD, persistently dysregulated; Rev, reversed.
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Time-dependent changes in gene expression in reverse LV remodeling. To investigate whether the expression of  
dysregulated HF genes in the reverse LV remodeled tTA-TRAF2dox4W mouse hearts was time dependent, we 
administered dox for an additional 4 weeks (a total of  8 weeks of  treatment) in a second cohort of  mice and 
then repeated transcriptional profiling. Similar to our findings in the 12-week-old tTA-TRAF2 mice, there 
were 3,095 incident HF genes in the 16-week-old tTA-TRAF2dox8W mouse hearts. However, of  the 3,095 
incident HF genes, 88% (2,724/3,095) of  these genes normalized in the tTA-TRAF2dox8W mice, whereas only 
12% (371/3,095) of  the incident HF genes remained persistently dysregulated HF in the tTA-TRAF2dox8W 
mouse hearts (Figure 6). Interestingly, 70% (885/1,256) of  the differentially expressed genes in the reverse 
LV remodeled hearts were not detected during LV remodeling and thus represent a set of  genes that were 
unique to reverse LV remodeling genes (see online Supplemental Table 3 for further characterization).
In contrast to the findings observed following 4 weeks of  dox treatment, unsupervised hierarchi-
cal clustering showed that the gene profiles for the LM, LMdox8W, and tTA-TRAF2dox8W hearts grouped 
together, whereas the genes for the tTA-TRAF2 mice clustered separately, suggesting that longer admin-
istration of  dox led to more complete normalization of  gene expression in the tTA-TRAF2dox8W mice 
(Figure 6C). To further explore the differences in gene profiles in the LV remodeled and reverse LV 
remodeled cardiac phenotypes, we performed a PCA. As shown in Figure 6D, the values for the PCA 
vectors for the LM, LMdox8W, and tTA-TRAF2dox8W hearts clustered together and were separate from 
the values for the PCA vectors for the tTA-TRAF2 hearts, consistent with the findings obtained with 
hierarchical clustering shown in Figure 6B. Interestingly, a KEGG functional analysis of  the changes in 
gene expression (Supplemental Figure 3) again identified significant changes in gene expression path-
ways implicated in both hypertrophic (P = 6.3 × 10–2) and DCM (P = 1.1 × 10–2) in the reversed inci-
dent HF genes in the tTA-TRAF2dox hearts. Figure 6E illustrates a diagram of  cardiac hypertrophy/
DCM–related cardiac myocyte genes displayed as reversed incident HF genes and persistently dysregu-
lated HF genes in the reverse LV remodeled tTA-TRAF2dox8W mouse hearts (See Supplemental Table 
Figure 5. Effect of transaortic 
constriction (TAC) on LV struc-
ture and mortality in LMdox4W and 
tTA-TRAF2dox4W mice. (A) LV mass 
index (LVMI), (B) LV wall thick-
ness (LVWTh), (C) LV end-diastolic 
diameter (LVEDD), and (D) LV r/h 
ratio at 2 and 4 weeks after TAC 
(baseline n = 7, 2 weeks after TAC n 
= 8–9, 4 weeks after TAC n = 5). (E) 
Kaplan-Meier analysis of survival 
in LMdox and tTA-TRAF2dox mice 
following TAC (n = 12 LMdox4W hearts 
and n = 14 tTA-TRAF2dox4W hearts). 
Statistical analysis performed 
using a repeated measures analysis 
using mixed models methodology 
(See Methods section). (*P < 0.05)
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4 for gene lists). Figure 6F shows a heat map of  changes in the reversed and persistently dysregulated 
genes grouped into 1 of  5 different functionally related cardiac myocyte gene modules. Figure 7A com-
pares and contrasts the changes in the number of  reversed and persistently dysregulated genes in the 
tTA-TRAF2dox hearts following 4 and 8 weeks of  dox. The important finding revealed by panel 7A is 
that there was an approximately 2-fold increase in the number of  reversed incident HF genes and an 
approximately 5-fold decrease in the dysregulated HF genes in the tTA-TRAF2dox8W hearts when com-
pared with tTA-TRAF2dox4W hearts. Figure 7B summarizes the percentage of  genes in each module that 
normalized after 4 and 8 weeks of  dox. As show, there was a greater reversal in incident HF genes for 
each of  the gene modules after 8 weeks of  treatment, with the greatest percentage of  reversed incident 
HF genes for the sarcomeric genes (~35%). Figure 7C shows that there was a striking decrease in the 
percentage of  persistently dysregulated HF genes within each of  the 5 gene modules following 8 weeks 
of  treatment with dox. Indeed, save for the persistently dysregulated incident HF metabolism genes, all 
of  the other persistently dysregulated genes in the cardiac myocyte gene modules were <3 % at 8 weeks. 
Of  note, while 12% of  the overall genes remained persistently dysregulated in the tTA-TRAF2dox8W mice 
treated with dox for 8 weeks, <1 % of  these genes were related to LV structure and/or function.
To determine the functional significance of  the abnormal gene expression profile in the tTA-TRAF2dox8W 
mice, we performed TAC on tTA-TRAF2dox8W and LMdox8W mice. Figure 8 shows that superimposition of  a 
hemodynamic pressure overload resulted in a significant overall increase in LV mass index (P < 0.001) and 
LV wall thickness (P < 0.001), along with a significant decrease in the r/h ratio (P = 0.005) in the LMdox8W 
and tTA-TRAF2dox8W mouse hearts. Importantly, however, there was no significant difference in the LV mass 
index (P = 0.12 ), LV wall thickness (P = 0.07), LVEDD (P = 0.86), and r/h ratio (P = 0.28) between the 
tTA-TRAF2dox8W and LMdox8W mouse hearts. Kaplan-Meier analysis showed that there was also not a sig-
nificant difference in mortality in the tTA-TRAF2dox8W mice when compared with LMdox8W mice (P = 0.54). 
Thus, a greater degree of  normalization of  the persistently dysregulated genes in the tTA-TRAF2dox8W mouse 
hearts was associated with a normalization of  the physiological response to a superimposed hemodynamic 
pressure overload.
To determine whether the observed changes in gene expression during reverse remodeling in the tTA-
TRAF2dox hearts were also observed in human HF, we examined changes in gene expression in the LV of  
patients with DCM before and after hemodynamic unloading with a left ventricular assist device (LVAD), 
in comparison to nonfailing (NF) human LV that could not be transplanted for technical reasons. We have 
reportedly previously that the LVAD-supported hearts used for these studies undergo reverse LV remod-
eling following LVAD support; however, none of  these patients could be weaned from LVAD support 
prior to cardiac transplantation (7). Figure 9A shows there were 1,928 incident HF genes in the failing 
human hearts and that 42% (810/1,928) of  these genes normalized following LVAD support, whereas 58% 
(1,118/1,928) of  the incident HF genes remained persistently dysregulated. Analogous to changes in gene 
expression observed in reverse LV remodeling in the tTA-TRAF2dox mice treated with dox for 4 weeks, 
60% (1,670/2,788) of  the differentially expressed genes in the LVAD-supported hearts were new reverse 
remodeling genes (see Supplemental Table 5 on online supplement). Unsupervised hierarchical clustering 
(Figure 9B) of  mRNA expression in the NF, DCM, and DCM after LVAD showed that the gene expression 
profiles of  the LVAD-supported DCM hearts were indistinguishable from that of  the pre-LVAD supported 
hearts. Similarly, the PCA analysis showed that the values for the PCA vectors of  the DCM and post-LVAD 
DCM hearts were grouped together and were distinct from the PCA vectors for NF human hearts. Figure 
9D shows that 23 of  25 (92%) cardiac hypertrophy/DCM incident HF genes were persistently dysregulated 
in the DCM-LVAD supported hearts, whereas only 2 of  25 (8%) of  the incident HF myocyte genes were 
reversed. The only gene module with reversal of  incident HF genes was the sarcomere gene module, with 
2 of  15 (13%) of  the incident HF genes reversed (Figure 9E). Of  note, the greatest overlap of  dysregu-
lated human HF genes with the dysregulated genes in the tTA-TRA2dox4W/tTA-TRA2dox8W hearts for the 
metabolism/energetics gene module (100% human genes detected in the mouse models), followed by the 
sarcomere gene module (75% human genes detected in the mouse models), and lesser overlap for the gene 
modules for matrix/cytoskeleton (43% human genes detected in the mouse models), excitation contraction 
coupling (33% human genes detected in the mouse models), and integrin/cytoskeleton (25% human genes 
detected in the mouse models). However, this comparison must be regarded as provisional because of  the 
different platforms used for transcriptional profiling, as well as the differences in tissue handling of  the 
murine and human myocardial samples.
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Figure 6. Transcriptional profiling in 16-week LM, tTA-TRAF2, LMdox8W, and tTA-TRAF2dox8W mouse hearts. (A) 
tTA-TRAF2 mice and LM controls were followed up to 8 weeks of age and were then randomized to receive doxycy-
cline in the drinking water or no doxycycline for 8 weeks. (B) Venn diagram of normalized heart failure (HF) genes, 
persistently dysregulated HF genes, and new reverse remodeled genes (see text for details). (C) Unsupervised 
hierarchical clustering of changes in gene expression and (D) principal component analysis (PCA) of changes in 
gene expression. (E) Illustration of persistently dysregulated and reversed HF genes in relation to their anatomic 
location within the cardiac myocyte. (F) Illustration of persistently dysregulated and reversed HF genes in gene 
modules relating to cardiac myocyte function (see text for details). The number of genes within each module is 
given in parenthesis (n = 4 hearts per group). Red indicates increased gene expression; blue indicates decreased 
gene expression relative to LM; Rev, reversed HF genes; PD, persistently dysregulated HF genes. Analysis was 
performed using Partek Genomic Suite. PC, principal component; PD, persistently dysregulated; Rev, reversed.
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Discussion
The results of  this study — in which we developed and characterized a conditional transgenic mouse model 
(tTA-TRAF2) that develops reversible DCM — provide 3 unique insights into the biology of  reverse LV 
remodeling. First, normalization of  LV structure (Figure 1, E–G) was associated with salutary changes 
in cardiac myocyte biology (Figure 2, A and B), including reversal of  cardiac hypertrophy and improved 
cardiac myocyte contractile function. The changes in cardiac myocyte biology occurred concurrently with 
improved LV chamber contractility and reverse LV remodeling (Figure 2, C–E). Importantly, the normal-
ization of  LV structure and function was not associated with a single gene, nor a single functional cardiac 
myocyte gene module. Rather, reversal of  the LV HF phenotype was accompanied by a coordinated change 
in the expression of  genes residing within multiple function gene modules (extracellular matrix, integrins/
cytoskeleton, excitation contraction-coupling, and the sarcomere). We also observed the emergence of  a 
number of  new genes during reverse LV remodeling, suggesting that reverse LV remodeling is not simply a 
reversal of  the genes that become dysregulated during LV remodeling, but rather is associated with coregu-
lation of  distinct sets of  novel genes that may be involved in tissue repair. It is noteworthy in this regard that 
a significant proportion of  the new reverse remodeling genes in the tTA-TRAF2dox4W mouse hearts were 
associated with gene ontologies involved in protein degradation, which are essential for tissue repair (8). 
To our surprise, reverse LV remodeling in the TRAF2dox4W mouse hearts was not associated with changes 
in the extracellular matrix (Figure 3), suggesting that improved myocyte contractile function is sufficient 
to lead to reverse LV remodeling and that changes in fibrillar collagen content are not required. Given that 
the amount of  fibrillar collagen content in the tTA-TRAF2 mice was modest, our findings do not obviate a 
potentially important role for the reversal of  myocardial fibrosis in different experimental models, wherein 
LV fibrosis is more prominent.
A second important observation was that the complete normalization of  LV structure and func-
tion in the tTA-TRAF2dox mice was accompanied by a partial (58%) normalization of  the genes that 
Figure 7. Analysis of reversed and 
persistently dysregulated genes in 
16-week LM, tTA-TRAF2, LMdox8W, 
and tTA-TRAF2dox8W mouse hearts. 
(A) Number of persistently dysregu-
lated and reversed heart failure (HF) 
genes after 4 and 8 weeks of doxycy-
cline. (B) Percentage of reversed HF 
genes in functional cardiac myocyte 
gene modules after 4 and 8 weeks 
of doxycycline. (C) Percentage of 
persistently dysregulated HF genes 
in functional cardiac myocyte gene 
modules after 4 and 8 weeks of 
doxycycline (n = 4 hearts per group). 
Analysis was performed using Partek 
Genomic Suite.
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became dysregulated during LV remodeling. Remarkably, both hierarchical clustering (Figure 4B) and 
PCA (Figure 4C) revealed that the gene expression profile observed in the tTA-TRAF2dox4W mice more 
closely resembled the gene profile in the tTA-TRAF2 hearts with an HF phenotype than the control 
mouse hearts that had normal LV structure and function. Thus, the normalization of  LV structure and 
function is dissociated from reversal of  the HF gene program during reverse LV remodeling. Impor-
tantly, similar findings with respect to persistent incident HF gene expression were also observed in the 
failing human hearts from patients that had a DCM whose hearts underwent reverse LV remodeling 
following LVAD support (Figure 9). Thus, our experimental findings are observed in humans and are 
likely not model dependent.
The third and perhaps most remarkable finding is that, when the tTA-TRAF2dox4W mice with persistent 
HF gene expression were stressed by superimposition of  a pressure overload, the tTA-TRAF2dox4W mouse 
hearts developed an exaggerated hypertrophic response at 2 and 4 weeks (Figure 5, A and B) that was 
associated with increased mortality (Figure 5E). Importantly, the exaggerated hypertrophic phenotype and 
increased mortality following pressure overload were not observed in the tTA-TRAF2dox8W mice, wherein 
there was a more complete (88%) reversal of  the incident HF genes and a nearly complete (97%) reversal of  
incident HF genes associated with cardiac myocyte contractility, suggesting that a more complete normal-
ization of  the HF gene program allows the heart to withstand a second stress imposed by a hemodynamic 
pressure overload. In this regard, it is interesting to note that cardiac decompensation frequently supervenes 
in HF patients following LVAD explantation, when the failing heart is exposed to loading conditions that 
are elevated relative to those encountered during hemodynamic support (9–11).
Reverse LV remodeling. Although reverse LV remodeling has been associated with favorable clinical 
outcomes in clinical studies, the extant literature suggests that the majority of  patients whose hearts 
Figure 8. Effect of transaortic constriction (TAC) on LV structure and mortality in LMdox8W and tTA-TRAF2dox8W mice. 
(A) LV mass index (LVMI), (B) LV wall thickness (LVWTh), (C) LV end diastolic diameter (LVEDD), and (D) LV r/h ratio at 
2 and 4 weeks after TAC (n = 7 hearts per group). (E) Kaplan Meier analysis of survival in LMdox and tTA-TRAF2dox mice 
following TAC (n = 7 LMdox8W hearts and n = 7 tTA-TRAF2dox8W hearts). Statistical analysis performed using a repeated 
measures analysis using mixed models methodology (see Methods section). (*P <0.05).
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undergo reverse LV remodeling may suffer from recurrent HF events despite apparent restoration of  nor-
mal LV structure and function, whereas a smaller number of  patients will remain free from recurrent HF 
events (3). Although the reasons for these discrepant outcomes are not known, multiple lines of  evidence 
support the point of  view that, in most instances, reverse LV remodeling does not lead to a normal heart, 
despite reversal of  many aspects of  the HF phenotype. In this regard, one of  the more interesting observa-
tions has been that the transcriptional changes that occur during reverse LV remodeling are not a simple 
inverse of  the changes that occurred during LV remodeling. Using a variety of  different models, including 
pharmacological (isoproterenol and angiotensin II infusion) (12), transgenic (conditional Akt overexpres-
sion) (13), and surgical (thoracic aortic banding and debanding models of  reversible cardiac hypertrophy) 
(14–16), investigators have shown that not only is there a persistence of  a subset of  genes that become dys-
regulated during pathological remodeling, but also that there are changes in the expression of  genes that are 
distinct from those that occur during pathological remodeling, indicating that there are unique sets of  genes 
that become altered during the regression of  pathological remodeling. Moreover, these genes belong to 
multiple functional gene ontogenies. Similar observations were reported by Margulies et al., who noted that 
more than 75% of  the dysregulated genes in failing human HF remained persistently dysregulated or were 
exacerbated following reversal of  the HF phenotype after LVAD support (17); he termed this “molecular 
hysteresis.” Whether this molecular hysteresis represents an adaptive response (i.e., transcriptional plastic-
ity) that allows cardiomyocytes to respond robustly to environmental stress, analogous to the phenomenon 
of  ischemic preconditioning, or whether it represents a maladaptive response because of  the inability to 
return to normalcy is not known.
The results of  the present study both confirm and extend prior observations by demonstrating that hearts 
that have not undergone complete genomic recovery are more vulnerable to a second hemodynamic stress, 
whereas hearts that have undergone complete transcriptional recovery are able to withstand hemodynamic 
overloading. The most parsimonious interpretation of  these observations is that a more complete reversal 
of  the HF gene program enables the heart to better withstand hemodynamic stress than a partial reversal of  
the HF gene program, insofar as the persistently dysregulated genes impair cardiac myocyte function and/
or are maladaptive. However, we cannot exclude the formal possibility that some of  the persistently dysregu-
lated or new reverse remodeling genes represent “susceptibility genes” that place the heart at risk during 
hemodynamic overload (e.g., Wnt signaling, MAPK signaling) (18, 19). Given that >55 % of  the incident 
HF genes in the hearts of  patients with DCM did not revert to normal following hemodynamic unloading 
with a LVAD, it is tempting to speculate that one of  the reasons these patients cannot be weaned from LVAD 
support — despite undergoing reverse LV remodeling — is because of  the persistence of  the abnormal HF 
gene program. Further studies will be necessary to address this question. Although we did not identify the 
mechanism(s) for the persistent dysregulated gene expression in the tTA-TRAF2dox4W mouse hearts, one 
intriguing observation is that changes in the epigenome may contribute to the persistent dysregulated genes.
Conclusion. The results of  this study demonstrate that reverse LV remodeling is associated with improve-
ments in the biology of  the adult cardiac myocyte, whereas changes in the fibrillar collagen content of  the 
heart are not necessary for restoration of  normal LV structure and function. Apart from the importance of  
these findings, the results of  this study also provide a unique glimpse into the biology of  the failing heart 
and show that the failing heart remains vulnerable to hemodynamic stress after restoration of  LV structure 
and function, and that this vulnerability diminishes over time. While our data suggest that this potential 
window of  vulnerability is secondary to an incomplete reversal of  the genes that become dysregulated dur-
ing LV remodeling, we cannot exclude the possibility that abnormalities of  the proteome and metabolome 
also play an important role. Although direct correlations between relatively short-term experimental studies 
in mice and long-term observations in the humans are not appropriate, these studies do raise the important 
question of  whether recurrent HF hospitalizations, which occur in ≥50% of  patients within the first 6 
Figure 9. Transcriptional profiling in nonfailing (NF) human hearts (n = 8) and paired failing human dilated cardiomyopathy (DCM) hearts (n = 8 
pairs) before and after LVAD. (A) Venn diagram of normalized heart failure (HF) genes, persistently dysregulated HF genes, and new reverse remod-
eled genes (see text for details). (B) Unsupervised hierarchical clustering of changes in gene expression, and (C) principal component analysis (PCA) of 
changes in gene expression.(D) Number of persistently dysregulated and reversed HF cardiac myocyte genes. (E) Illustration of persistently dysregu-
lated and reversed HF genes in gene modules relating to cardiac myocyte function (see text for details). The number of genes within each module is 
given in parenthesis. Red indicates increased gene expression; blue indicates decreased gene expression relative to LM; Rev, reversed HF genes; PD, 
persistently dysregulated HF genes. Analysis performed using Partek Genomics Suite. (F) Percentage of persistently dysregulated and reversed HF 
genes in functional cardiac myocyte gene modules after LVAD support. PC, principal component; PD, persistently dysregulated; Rev, reversed.
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months of  discharge (20), may in some way be related to the susceptibility of  the failing myocardium to a 
subsequent stress in patients who appear clinically stable at the time of  discharge from the hospital. Given 
that recurrent HF hospitalizations are regarded as a measure of  poor quality of  care, and that health care 
systems are being penalized for readmitting patients, the current study may have important health care 
implications in so far as recurrent hospitalization may be the only means to stabilize certain patients, as 
suggested by several clinical studies (21, 22). Finally, these observations may have implications with respect 
to the development of  new therapies that target the ensemble of  genes that place HF patients at risk for 
subsequent hemodynamic deterioration.
Methods
Generation of  tTA-TRAF2 transgenic mice. To develop an experimental model to study reverse LV remodeling, 
we generated a conditional transgenic mouse model (tTA-TRAF2) that overexpresses TRAF2 in the heart, 
using a cardiac-specific and tetracycline-transactivating factor–regulated promoter (23). The rationale for 
conditionally overexpressing TRAF2 in the heart was that we have shown previously that sustained expres-
sion of  TRAF2, a scaffolding protein that coordinates signaling through the type 1 and type 2 TNF recep-
tors, resulted in LV remodeling and LV dysfunction that phenocopies the LV remodeling and LV dysfunc-
tion observed with the development of  parainflammation in mice with cardiac restricted overexpression of  
TNF (4). Further, elevated levels of  myocardial TRAF2 have been reported to be elevated in HF patients 
(24). In this conditional “tet-off ” system, the stable tetracycline analog dox (Sigma-Aldrich) inhibits tTA 
transactivation of  the Traf2 transgene in the heart.
Briefly, a murine Traf2 cDNA (4) was cloned into a cardiac-specific, inducibly controlled vector composed 
of  a modified mouse α-myosin heavy chain (Myh6) minimal promoter fused with nucleotide binding sites 
for tTA (23). The transgene construct was injected into single cell embryos of  FVB mice at the Baylor 
College of Medicine (Houston, Texas, USA) transgenic core facility. Founder lines of  MYH6-TRAF2 
transgenic mice (FVB background) were identified by PCR and confirmed by Southern blotting using 
a 286 bp probe targeted to exon 8 of the Traf2 gene (Supplemental Figure 4A). Western blotting was 
performed to confirm the expression of  TRAF2 protein in the hearts of  12-week-old MYH6-TRAF2 
mouse hearts (Supplemental Figure 4B) using an anti-TRAF2 antibody (sc-877, Santa Cruz Biotech-
nology Inc.). We obtained 4 founder lines harboring 4, 5, 13, and 29 copies of  the Traf2 transgene. The 
founder line with 29 copies of  the transgene did not yield any progeny; therefore, we selected the MYH6-
TRAF2 founder line with 13 copies for further characterization. The MYH6-TRAF2 mice were crossed 
with mice that expressed tTA in the heart (MYH6-tTA [FVB background]), in order to generate lines of  
tTA-TRAF2 mice that conditionally express TRAF2 in the heart.
In preliminary control experiments, we determined that the cardiac-restricted Traf2 transgene 
expressed in the tTA-TRAF2 mice was completely silenced 1–2 weeks after adding dox to the drinking 
water (Supplemental Figure 4B). We further noted that the Traf2 transgene was rapidly reexpressed with-
in 1 week after removing dox from the drinking water (Supplemental Figure 4B). We also characterized 
lines of  LM, MYH6-TRAF2, and MYH6-tTA mice at 8, 12, and 16 weeks of  age to determine whether 
there was a baseline phenotype. As shown in Supplemental Figure 4C, there was no significant differ-
ence in HW/BW ratio in the LM, MYH6-TRAF2, and MYH6-tTA mice at any time point. Further, 2-D 
echocardiography revealed there was no significant difference in the LVEDD nor LV posterior wall thick-
ness in 12-week-old LM, MYH6-TRAF2, and MYH6-tTA mice (Supplemental Figure 4D). As shown 
in Supplemental Figure 4E, there was no significant difference in LV contractility, measured as LVDP, in 
12-week-old LM, MYH6-TRAF2, and MYH6-tTA hearts.
All mice were housed under standard environmental conditions and were fed commercial chow and 
tap water ad libitum.
Characterization of  tTA-TRAF2 transgenic mice. Provisional characterization of the tTA-TRAF2 mice that 
were fed commercial chow and tap water ad libitum showed that these mice reliably developed a dilated LV 
HF phenotype by 8 weeks of age. To determine whether this dilated phenotype was reversible, both LM and 
the tTA-TRAF2 mice were randomized to receive either tap water or tap water with dox (0.5 mg/cc, changed 
3 times weekly) for a period of 4 weeks. Given that the Myh6-tTA transgene has been associated with effects on 
myocardial gene expression (6), we used MYH6-tTA mice as the appropriate genotype for LM control mice. 
Four groups of mice were characterized for these studies: LM, LMdox4W, tTA-TRAF2, and tTA-TRAF2dox4W. 
The animals were euthanized at 12 or 16 weeks of age for the purpose of the studies delineated below.
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LV structure. Cardiac hypertrophy was assessed by measuring the HW/BW ratio of  the LM, LMdox4W, 
tTA-TRAF2, and tTA-TRAF2dox4W mice at 12 weeks of  age. Two-dimensional–targeted M-mode echocar-
diography was used to measure LV structure at 8, 12, and 16 weeks of  age, as described (25). Anesthesia 
was induced using 2% isoflurane and was maintained using 1% isoflurane. Throughout the 2-D echocar-
diographic studies, care was taken to maintain the heart rate above 400 bpm by adjusting the level of  anes-
thesia. All 2-D and M-mode echocardiographic measurements were performed by an investigator who was 
blinded to the experimental group that was being studied.
Isolated cardiac myocyte contractility. Isolated ventricular myocytes were prepared from LM, LMdox4W, 
tTA-TRAF2, and tTA-TRAF2dox4W mice at 12 weeks of  age, as described (26). Sarcomere length from sin-
gle cardiac myocytes was recorded using an epi-fluorescence inverted microscope (Nikon TS100) with an 
attached CCD camera (IonOptix MyoCam, IonOptix). In these experiments, an aliquot of  cardiomyocytes 
was placed into a small superfusion chamber that received a buffer (20 mM HEPES [pH 7.4], 1 mM CaCl2, 
137 mM NaCl, 5.4 mM KCl, 15 mM dextrose, 1.3 mM MgSO4, and 1.2 mM NaH2PO4). All measurements 
were made on rod-shaped myocytes that had regular well-defined striations. Cardiomyocytes were field 
stimulated using platinum electrodes. Steady-state trains of  stimuli (2 ms) were applied at a frequency of  
0.5 Hz. Sarcomere motion and fluorescence were recorded continuously using IonOptix acquisition soft-
ware, and the data were stored for an off-line analysis by IonWizard software (IonOptix 1999, version 5). 
Unloaded sarcomere shortening was calculated based on the difference between peak systolic length and 
maximum diastolic length.
LV function. Hearts from LM, LMdox4W, tTA-TRAF2, and tTA-TRAF2dox4W mice at 12 weeks of  age 
were freshly excised and buffer perfused in the Langendorff  mode, as described (27). The hearts were paced 
from the right ventricle using a Grass SD9 stimulator (Grass Instruments) at 420 bpm. Functional data 
were recorded at 1 KHz on a data acquisition system (PowerLab, ADInstruments). After 20 minutes of  
stabilization, the balloon was progressively inflated in 5-μl increments until LVDP became asymptotic and 
then began to decline. LVDP was calculated as the difference between peak-systolic pressure and LVEDP. 
LV peak + LV dP/dt and peak – LV dP/dt were determined at peak LVDP.
Myocardial fibrosis. Perfusion-fixed hearts from LM, LMdox4W, tTA-TRAF2, and tTA-TRAF2dox4W mice 
were obtained at 12 weeks and were embedded in paraffin and stained using the picrosirius red technique, 
as described (28). To calculate the extent of  myocardial fibrosis, the LV was divided into 8 quadrants, and 
the percent area of  extracellular picrosirius red staining was computed from random images obtained in 
each quadrant. Large epicardial arteries and/or veins were excluded, as well as any cutting and/or com-
pression artifacts.
Gene expression profiling. Transcriptional profiling of  LM, LMdox4, tTA-TRAF2, and tTA-TRAF2dox mice 
at 12 and 16 weeks of  age was performed using the Sentrix BeadChip and BeadStation system from Illumi-
na Inc. Total RNA was converted to cDNA by reverse transcription using Superscript II reverse transcrip-
tase and T7-(dT)24 primers, followed by second-strand synthesis to generate double-stranded cDNA. After 
purification, the cDNA was converted to biotin-labeled cRNA, hybridized to a mouse Ref-8 BeadChip 
array (Illumina Inc.), and stained with strepavidin-Cy3 for visualization. The mouse Ref-8 BeadChips con-
tain sequences representing approximately 24,000 curated genes and expressed sequence tags (ESTs). Qual-
ity standards for hybridization, labeling, staining, background signal, and basal level of  housekeeping gene 
expression for each chip were verified. After scanning the probe array, the resulting image was analyzed 
using the GenomeStudio software (Illumina Inc.). Raw expression data was subjected to filtering, log trans-
formation, and quantile normalization for further analysis using PARTEK Genomics Suite (Partek Inc.). 
Significant genes in LV remodeled hearts (LM vs. tTA-TRAF2) and reverse LV remodeled hearts (LMdox 
vs. tTA-TRAF2dox) were identified using ANOVA with contrasts. A fold-change cut-off  of  1.2 was utilized 
in all group comparisons. Agglomerative hierarchical clustering was performed by using an average linkage 
algorithm with euclidean distance measure based on expression levels of  significant HF genes determined 
by SAM analysis (false called number of  10).
PCA. Global mRNA and miRNA expression data from 4 groups of  mice were also examined using PCA, 
which is a mathematical modeling procedure that transforms a number of  possibly correlated variables into 
a smaller number of  uncorrelated variables termed principal components (29). PCA allows the complex data 
sets to be visualized in a simple 3-D display format, wherein the x-axis displays the values for the first principal 
component, the y-axis displays the values for the second principal component, and the z-axis displays the val-
ues for the third principal component. Functional annotation clustering of  genes differentially expressed dur-
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ing LV remodeling and reverse LV remodeling based on gene ontology classification and the KEGG pathways 
database was performed using publicly available DAVID v6.7 software (http://david.abcc.ncifcrf.gov/) (30).
To compare the findings obtained in the tTA-TRAF2 mouse hearts with a clinically relevant model of  
reverse LV remodeling, we examined changes in gene expression in human NF and paired DCM hearts 
before and after hemodynamic unloading with a LV assist device using deep RNA sequencing, as described 
(7). Deep sequencing data have been submitted to the National Center for Biotechnology Information gene 
expression and hybridization array data repository (GEO ID: GSE46224). The duration of  LVAD support 
in this patient cohort was 10.1 ± 1.7 months. The myocardial mRNA expression profiles used for the pres-
ent analysis have been reported previously as an online supplement (see Supplemental Table 6 in ref. 7); 
however, the informatics analysis of  these genes presented here has not been reported previously. Briefly, 
using 2-tailed adjusted P < 0.05 and a 1.2-fold change cut-off, we compared changes in gene expression in 
NF vs. DCM hearts and DCM-LVAD–supported vs. NF LV tissues. Agglomerative hierarchical clustering, 
PCA, and KEGG pathway analysis were performed as described above.
Transverse aortic constriction. In parallel studies, we performed TAC in LMdox and tTA-TRAF2dox mice 
that had received dox in the drinking water from 8–12 weeks of  age or from 8–16 weeks of  age (31). In brief, 
mice were anesthetized with a mixture of  xylazine (10 mg/kg) and ketamine (100 mg/kg), and the TAC 
procedure was performed by a surgeon blinded to the status of  the mice. LMdox and tTA-TRAF2dox mice 
subsequently underwent serial 2-D echocardiographic imaging for LV structure and function at 2 and/or 4 
weeks after TAC. Echo-imaging for the TAC studies was performed with the mice in a semiconscious state 
under low dose Avertin anesthesia (0.05 mg/g IP). The animals were euthanized 4 weeks following TAC, 
and the hearts were excised for determination of  HW/BW ratio.
Statistics. Data are expressed as mean ±SEM. Two-way ANOVA testing was used to test for time-
dependent differences in HW/BW ratios, 2-D echocardiographic parameters, LVDP, +dP/dT, –dP/dT, 
fibrillar collagen content, and sarcomere shortening between groups; post-hoc comparisons of  changes in 
these parameters between groups at a particular time were performed, where appropriate, using Tukey’s 
test. Analysis of  LV structure after TAC was performed using a repeated measures analysis using mixed 
models methodology. Group, time, and the interaction between group and time were all included in the 
model. Time (baseline, 1 week, 2 weeks, and 4 weeks) was treated as a categorical variable. Based on the 
Akaike Information Criteria (AIC) and Shwarz Bayesian Information Critieria (BIC), an autoregressive 
covariance structure was used to model the repeated measurements. Group means and standard errors 
were based on model results. Tests to evaluate differences were conducted overall and at each time point. 
All analysis conducted in SAS v9.4 (SAS Institute Inc.). A P value of  ≤ 0.05 was considered statistically 
significant in all comparisons.
Study approval. All animal studies conformed with the principles of  the NIH Guide for the Care and Use 
of  Laboratory Animals (8th ed. National Academies Press. 2011.) and were approved by the Institutional 
Animal Care and Use Committee of  Baylor College of  Medicine and Washington University School of  
Medicine. All studies using human tissue were conducted in accordance with protocols approved by the 
Washington University and Columbia University IRBs.
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